Disease on EC 1.1.1.149 - 20alpha-hydroxysteroid dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
20alpha-hydroxysteroid dehydrogenase deficiency
Regulation of progesterone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20alpha-hydroxysteroid dehydrogenase.
Adenocarcinoma
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
Adenoma
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
Astrocytoma
Inducible protection of human astrocytoma 1321N1 cells against hydrogen peroxide and aldehyde toxicity by 7-hydroxycoumarin is associated with the upregulation of aldo-keto reductases.
Blast Crisis
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Breast Neoplasms
11?-Prostaglandin F2?, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638.
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Correlation of Aldo-Ketoreductase (AKR) 1C3 Genetic Variant with Doxorubicin Pharmacodynamics in Asian Breast Cancer Patients.
Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy.
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk.
Hormone-related pathways and risk of breast cancer subtypes in African American women.
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents.
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling.
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17?-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.
Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Carcinogenesis
Basal and Regulatory Promoter Studies of the AKR1C3 Gene in Relation to Prostate Cancer.
Carcinoma
11?-Prostaglandin F2?, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress.
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Increased expression of type 2 3{alpha}-hydroxysteroid dehydrogenase/type 5 17{beta}-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Inhibitors of human 20?-hydroxysteroid dehydrogenase (AKR1C1).
Integration of HPV6 and Downregulation of AKR1C3 Expression Mark Malignant Transformation in a Patient with Juvenile-Onset Laryngeal Papillomatosis.
Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase.
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.
The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoateinduced esophageal squamous cell carcinoma cell death.
Carcinoma, Ductal
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Carcinoma, Hepatocellular
Gene expression profiles of HeLa Cells impacted by hepatitis C virus non-structural protein NS4B.
Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase.
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Carcinoma, Renal Cell
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Carcinoma, Small Cell
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Carcinoma, Squamous Cell
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoateinduced esophageal squamous cell carcinoma cell death.
Cardiomyopathies
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Choriocarcinoma
AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells.
Colonic Neoplasms
Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A.
Colorectal Neoplasms
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Dehydration
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Endometrial Hyperplasia
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Endometrial Neoplasms
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1.
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Endometriosis
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1.
Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2? biosynthesis and action in ovarian endometriosis tissue and in model cell lines.
Expression of human aldo-keto reductase 1C2 in cell lines of peritoneal endometriosis: Potential implications in metabolism of progesterone and dydrogesterone and inhibition by progestins.
Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Epilepsy
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1.
Esophageal Neoplasms
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Fetal Resorption
An enzymologic study of corpora lutea in early pregnant rats treated with abortifacient agents.
Glioblastoma
A network model of a cooperative genetic landscape in brain tumors.
Glioma
Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis.
Hepatitis B
Hepatitis B Virus X Protein Up-Regulates AKR1C1 Expression Through Nuclear Factor-Y in Human Hepatocarcinoma Cells.
Herpes Zoster
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
Histochemical studies of 3 beta- and 20alpha-hydroxysteroiddehydrogenase in the adrenals and ovaries of the nu/nu mouse.
Type 5 17{beta}-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in adrenal reticularis.
Hypospadias
Fine mapping analysis confirms and strengthens linkage of four chromosomal regions in familial hypospadias.
Keloid
The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids.
Kidney Neoplasms
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Leukemia
Identification of aldo-keto reductases as NRF2-target marker genes in human cells.
Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia.
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Leukemia, Myeloid
Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Leukemia, Myeloid, Acute
Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Liver Diseases, Alcoholic
Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
Lung Neoplasms
Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
Exposure to airborne PM2.5 suppresses microRNA expression and deregulates target oncogenes that cause neoplastic transformation in NIH3T3 cells.
Finding Genes Discriminating Smokers from Non-smokers by Applying a Growing Self-organizing Clustering Method to Large Airway Epithelium Cell Microarray Data.
High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells.
NNK reduction pathway gene polymorphisms and risk of lung cancer.
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions.
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Lymphoma, Non-Hodgkin
Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin Lymphoma.
Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma.
Medulloblastoma
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Meningioma
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Metabolic Diseases
Regulation of human aldoketoreductase 1C3 (AKR1C3) gene expression in the adipose tissue.
Neoplasm Metastasis
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Neoplasms
A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Activation of AKR1C1/ER? induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Androgenic and estrogenic 17beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: evidence for the type 1, 2 and 5 isoforms.
Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling.
Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
Chinese Red Yeast Rice Inhibition of Prostate Tumor Growth in SCID Mice.
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.
Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.
Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3.
Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress.
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells.
Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells.
Influence of Aldo-keto reductase 1C3 in prostate cancer -a mini review.
Inhibitors of human 20?-hydroxysteroid dehydrogenase (AKR1C1).
Inhibitors of type 5 17?-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights.
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer.
Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors.
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Localization and altered expression of AKR1C family members in human ovarian tissues.
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Progesterone metabolism in normal human endometrium during the menstrual cycle and in endometrial carcinoma.
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling.
Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth.
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.
Structure of AKR1C3 with 3-phenoxybenzoic acid bound.
Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A.
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17?-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.
Transcript level of AKR1C3 is down-regulated in gastric cancer.
Nervous System Diseases
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Neurilemmoma
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Obesity, Abdominal
Expression and activity of 20alpha-hydroxysteroid dehydrogenase (AKR1C1) in abdominal subcutaneous and omental adipose tissue in women.
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity.
Papilloma
Integration of HPV6 and Downregulation of AKR1C3 Expression Mark Malignant Transformation in a Patient with Juvenile-Onset Laryngeal Papillomatosis.
Polycystic Ovary Syndrome
Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome.
Pre-Eclampsia
[Microarray analysis of differentially expressed genes in peripheral leucocytes derived from severe preeclampsia and normotensive pregnancies]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
Premature Birth
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Prostatic Neoplasms
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-?-Hydroxysteroid Dehydrogenase AKR1C3.
3D-QSAR studies of 3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids as AKR1C3 inhibitors: Highlight the importance of molecular docking in conformation generation.
Activin A stimulates AKR1C3 expression and growth in human prostate cancer.
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
AKR1C3 as a target in castrate resistant prostate cancer.
AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638.
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Basal and Regulatory Promoter Studies of the AKR1C3 Gene in Relation to Prostate Cancer.
Canonical Androstenedione Reduction is the Predominant Source of Signalling Androgens in Hormone Refractory Prostate Cancer.
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.
Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17?-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer.
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17?-hydroxysteroid dehydrogenase type 5 (17?HSD5; AKR1C3).
Inhibitors of type 5 17?-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights.
Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer.
In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis.
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Microarray analysis of survival pathways in human PC-3 prostate cancer cells.
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5?-reductase inhibitor finasteride.
Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.
Prostate cancer: ERG fusion and AKR1C3 form AR signalling feed-forward loop.
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Screening baccharin analogs as selective inhibitors against type 5 17?-hydroxysteroid dehydrogenase (AKR1C3).
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Selective inhibition of human type-5 17?-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth.
Structure of AKR1C3 with 3-phenoxybenzoic acid bound.
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17?-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.
Psoriasis
Aldo-Keto Reductase 1C3 Is Expressed in Differentiated Human Epidermis, Affects Keratinocyte Differentiation, and Is Upregulated in Atopic Dermatitis.
Skin Neoplasms
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Stomach Neoplasms
Transcript level of AKR1C3 is down-regulated in gastric cancer.
Urinary Bladder Neoplasms
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Association of AKR1C3 Polymorphisms with Bladder Cancer.
Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes.
Variation in Genes Encoding the Neuroactive Steroid Synthetic Enzymes 5?-Reductase Type 1 and 3?-Reductase Type 2 Is Associated With Alcohol Dependence.
Uterine Cervical Neoplasms
Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Uterine Diseases
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases.
Wilms Tumor
Differential expression of type 2 3?/type 5 17?-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.